RxDoctor Payments DataLook up a doctor →

Joshua Ramsay, DO

Hematology & Oncology · Ogden, UTNPI 1093245607

Payments from drug & device makers

$14,083in general payments, 2019–2025

Across 621 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$899
  • Merck$817
  • Incyte Corporation$793
  • Pfizer$734
  • Seagen Inc.$666
  • plus $8K from 54 others
$1,531in research payments, 2019–2025

Across 9 payments — averaging $170.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis81$1,745
AstraZeneca42$899
Merck38$817
Incyte Corporation30$793
Pfizer44$734
Seagen Inc.13$666
Johnson & Johnson27$548
AbbVie19$537
GSK29$530
Daiichi Sankyo Inc.20$512
Bristol Myers Squibb21$491
Genentech USA, Inc.18$415
Eisai Inc.17$405
Lilly USA, LLC13$397
Pharmaessentia USA Corporation20$350
Beigene USA, Inc.8$298
Genmab U.S., Inc.14$278
Sanofi12$253
EMD Serono, Inc.7$220
E.r. Squibb & Sons, L.L.C.11$214
Regeneron Healthcare Solutions, Inc.9$192
Takeda Pharmaceuticals U.S.A., Inc.8$174
Gilead(2 entities)10$173
Amgen4$148
Blueprint Medicines Corporation1$129
Bayer6$122
Geron Corporation5$118
Sumitomo Pharma America, Inc.6$112
Amneal Pharmaceuticals LLC5$108
Rigel Pharmaceuticals, Inc.4$105
Jazz Pharmaceuticals Inc.6$97
Sobi, Inc4$93
Astellas Pharma US Inc4$89
Tersera Therapeutics LLC4$86
Pharmacosmos Therapeutics Inc.4$79
Servier Pharmaceuticals LLC3$71
Springworks Therapeutics, Inc.3$68
Boehringer Ingelheim3$68
Array Biopharma Inc3$61
Puma Biotechnology, Inc.4$61
Coherus Oncology, Inc.2$60
Organon4$52
Agios Pharmaceuticals, Inc.3$49
Novo Nordisk1$45
Fennec Pharmaceuticals, Inc.3$43
Deciphera Pharmaceuticals Inc.2$41
Exelixis Inc.2$41
Azurity Pharmaceuticals, Inc.2$40
Recordati_rare_diseases_inc.2$38
AVEO Pharmaceuticals, Inc.1$38
ADC Therapeutics America, Inc.2$37
Tempus AI, Inc1$28
Dendreon Pharmaceuticals LLC1$28
Nuvation Bio Inc.1$25
Immunocore Limited1$24
Mirati Therapeutics, Inc.1$24
Iovance Biotherapeutics, Inc.1$23
Accord Healthcare, Inc.1$22
Sanofi-aventis U.S. LLC1$21
Syndax Pharmaceuticals, Inc.1$19

How this compares

$14,083 in reported general payments places this provider in the 50th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah →

Medicare billing

Part B allowed, 2024
$2,020,148
Medicare patients
417
Services billed
148,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →